NEW YORK (GenomeWeb) – Germany-based BioNTech Diagnostics and Shuwen Biotech, its partner in China, announced that their MammaTyper real-time PCR breast cancer stratification kit has been granted an expedited review for regulatory approval by the China Food and Drug Administration (CFDA).

The agency will review the diagnostic under a special process designed to expedite the approval of innovative products, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.